Explore our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts.

March 24 – 30 2025

Pα+ Psychedelic Bulletin #192

Psychedelic Alpha ↗

  • Psychedelic Safety Takes Centre Stage in Berkeley
  • Selection Bias and Small Sample Size Hampers Compass Pathways’ Long-Term Psilocybin Data
  • Placebo Outperforms LSD in MindMed’s Microdosing Study for ADHD
  • atai Bets on Bitcoin
  • Potential Tweak to Ukrainian Law Could Permit Psychedelic Research
  • Governor of Virginia Vetoes Compass Pathways Rescheduling Bill
  • and much more…

May 19 – 25, 2025

Pα+ Psychedelic Bulletin #198

Psychedelic Alpha ↗

  • New Data Offers Look at Spravato’s Long-Term Use, Highlights Opportunity for Psychedelics
  • MAHA Report Slams Psychiatric Drug Use Among America’s Youth
  • Beckley’s Small Study Supports Adjunctive Use of 5-MeO-DMT with SSRIs in TRD
  • and more…

March 17 – 23 2025

Pα+ Psychedelic Bulletin #191

Psychedelic Alpha ↗

  • De-Weirding Psychedelics, SXSW
  • Psilocybin for Alcohol Use Disorder: Swiss Study Finds No Impact on Drinking
  • HALT Fentanyl Act Could Streamline Schedule I Research
  • Compass Pathways on Phase 3, REMS, and Potential Tailwinds
  • Government Accountability Office Issues Note on Psychedelics
  • and much more…

March 3 – 9 2025

Psychedelic Bulletin #190: ‘Europe’s Most Feared Investor’ Teams Up with Musk Associate to Fund Lykos Therapeutics

Pα+ Psychedelic Bulletin #190

Psychedelic Alpha ↗

  • ‘Europe’s Most Feared Investor’ Teams Up with Musk Associate to Fund Lykos Therapeutics
  • Risk-Off or Reality Check? Psychedelic Stocks Slump After RFK Jr. Surge
  • Beckley Wraps Enrolment for Phase 2b Study of 5-MeO-DMT in Treatment-Resistant Depression
  • and more…

February 24 – March 2, 2025

Pα+

An insider’s guide to the business,
policy and science of psychedelics.

Basic

Free subscribers receive a weekly round-up
of news on psychedelics, as well as the occasional article.

Receive regular bulletins, articles, interviews with insiders and quick-take analysis of major stories and developments.

Teams

Teams, groups and corporate pricing plans are available, please get in touch via email
to learn more.

Benefits

Front-row access to the psychedelics space: breaking bulletins, in-depth articles, insider interviews and sharp analysis of the moments that matter—from major trial results and funding rounds to policy shifts shaping the future. Plus, full access to our complete
archive and Library.

Learn More
  Free
Weekly Psychedelic News Feed
Occasional Articles & Free Resources
Psychedelic Bulletins (In-Depth Briefings, Multiple per Month)
Quick-Take Analysis of Major Developments
In-Depth Articles & Deep Dives
Exclusive Interviews with Insiders & KOLs
Quarterly Video Briefings
Exclusive Tools & Data Resources
Library of Primers & Explainers

Subscribe Now

Monthly $20 Annually $200

Join Today

Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.

Monthly $20 Annually $200

Subscribe to our
free newsletter


By signing up, you agree to our privacy policy. You can unsubscribe at any time.

Learn More About

Group, team &
corporate plans


Aside from group pricing, we also offer bespoke reports and regular briefings. Get in touch to discuss.